// App-Quantinova.ai

508 : Generalizability of predictive versus prognostic indicators from published transcriptomic associations with tumor response to immune checkpoint inhibition

Researchers

Presenter

  • Dante Bortone

Principal Investigators

  • Nicholas Tschernia

  • Alexandria Cogdill

  • Yana Najjar

  • Randy F Sweis

  • Sara Valpione

  • Erik Wennerberg

  • Praveen Bommareddy

  • Cara Haymaker

  • Uqba Khan

  • Heather M McGee

  • Wungki Park

  • Houssein A Sater

  • Christine Spencer

  • Maria Ascierto

  • Valentin Barsan

  • Vinita Popat

  • Daniel Wells

  • Steven Vensko

  • Sarah Dexheimer

  • Vesteinn Thorsson

  • Roberta Zappasodi

  • Nils-Petter Rudqvist

  • Benjamin Vincent

Medical Centers

  • National Cancer Institute, Bethesda, United States

  • Radiology, Weill Cornell Medicine New York NY United States

  • Jewish General Hospital, Montreal, QC, Canada

  • Stanford University School of Medicine, Portola Valley, United States

  • Providence Saint John’s Cancer Institute, Santa Monica, CA, United States

  • The Institute of Cancer Research, London, UK

  • University of Chicago, Chicago, IL, United States

  • Immunai, New York, NY, United States

  • UPMC Hillman Cancer Center, Pittsburgh, PA, USA

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • University of Texas Southwestern, Dallas, TX, United States

  • Weill Cornell Graduate School of Medical Sciences, San Francisco, CA, United States

  • Cleveland Clinic Florida, Stuart, FL, United States

  • Weill Cornell Medical College of Cornell University, San Francisco, CA, United States

  • City of Hope, Duarte, California, United States

  • The Christie NHS Foundation Trust, Manchester,

  • Parker Institute for Cancer Immunotherapy, San Francisco, CA

  • Institute for Systems Biology Seattle WA United States

  • University of North Carolina at Chapel Hill, Chapel Hill, NC, United States

  • Memorial Sloan-Kettering Cancer Center, New York, NY, United States

Locations

  • United States

  • United Kingdom

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved